Onco-Innovations Extends Marketing Program
Onco-Innovations (OTCQB:ONNVF) has announced the extension of its marketing engagement with MCS Market Communication Service GmbH through May 31, 2025. The company has allocated CAD 600,000 for the extended services, which include campaign creation, marketing materials production, and research and analytics.
The marketing services will be delivered through digital channels, specifically Google Ads and native advertising. The agreement will continue until the specified end date or until the budget is exhausted. No securities were issued as compensation for these services.
Onco-Innovations (OTCQB:ONNVF) ha annunciato l'estensione del suo impegno di marketing con MCS Market Communication Service GmbH fino al 31 maggio 2025. L'azienda ha stanziato 600.000 CAD per i servizi estesi, che includono la creazione di campagne, la produzione di materiali di marketing e la ricerca e analisi.
I servizi di marketing saranno forniti attraverso canali digitali, in particolare Google Ads e pubblicità nativa. L'accordo continuerà fino alla data di scadenza specificata o fino all'esaurimento del budget. Non sono state emesse titoli come compenso per questi servizi.
Onco-Innovations (OTCQB:ONNVF) ha anunciado la extensión de su compromiso de marketing con MCS Market Communication Service GmbH hasta el 31 de mayo de 2025. La empresa ha asignado 600,000 CAD para los servicios extendidos, que incluyen la creación de campañas, la producción de materiales de marketing y la investigación y análisis.
Los servicios de marketing se ofrecerán a través de canales digitales, específicamente Google Ads y publicidad nativa. El acuerdo continuará hasta la fecha de finalización especificada o hasta que se agote el presupuesto. No se emitieron valores como compensación por estos servicios.
Onco-Innovations (OTCQB:ONNVF)는 MCS Market Communication Service GmbH와의 마케팅 계약을 2025년 5월 31일까지 연장한다고 발표했습니다. 회사는 연장된 서비스에 대해 600,000 CAD를 할당했으며, 여기에는 캠페인 생성, 마케팅 자료 제작 및 연구 및 분석이 포함됩니다.
마케팅 서비스는 디지털 채널을 통해 제공되며, 특히 Google Ads 및 네이티브 광고를 포함합니다. 계약은 지정된 종료일까지 또는 예산이 소진될 때까지 계속됩니다. 이러한 서비스에 대한 보상으로 증권이 발행되지 않았습니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé l'extension de son engagement marketing avec MCS Market Communication Service GmbH jusqu'au 31 mai 2025. L'entreprise a alloué 600 000 CAD pour les services prolongés, qui comprennent la création de campagnes, la production de matériel marketing et la recherche et l'analyse.
Les services marketing seront fournis par le biais de canaux numériques, notamment Google Ads et la publicité native. L'accord se poursuivra jusqu'à la date de fin spécifiée ou jusqu'à épuisement du budget. Aucun titre n'a été émis en compensation de ces services.
Onco-Innovations (OTCQB:ONNVF) hat die Verlängerung seines Marketingengagements mit MCS Market Communication Service GmbH bis zum 31. Mai 2025 bekannt gegeben. Das Unternehmen hat 600.000 CAD für die erweiterten Dienstleistungen bereitgestellt, die die Erstellung von Kampagnen, die Produktion von Marketingmaterialien sowie Forschung und Analysen umfassen.
Die Marketingdienstleistungen werden über digitale Kanäle bereitgestellt, insbesondere über Google Ads und Native Advertising. Die Vereinbarung wird bis zum angegebenen Enddatum oder bis das Budget erschöpft ist, fortgeführt. Es wurden keine Wertpapiere als Vergütung für diese Dienstleistungen ausgegeben.
- Enhanced digital marketing presence through Google Ads and native advertising channels
- Strategic investment in market visibility and brand awareness
- Significant marketing expense of CAD 600,000 impacts cash resources
VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the "Services"). The Services are expected to run until May 31, 2025, or until budget exhaustion. The Company has paid MCS CAD 600,000 for the extended term of Services, and no securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the Company's ability to complete future research and development activities with respect thereto, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to complete further research and development activities in respect thereto, the failure to receive regulatory approval in respect of its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
How much is Onco-Innovations (ONNVF) spending on its extended marketing program?
When does ONNVF's extended marketing program end?
What marketing services will MCS provide to ONNVF?
Did ONNVF issue any securities as compensation for the marketing services?
